CClinicalTrials.gg
CompletedNCT00302185Updated Oct 20, 2010

Acupuncture in Palliative Cancer Care

A Phase 3 interventional study of Acupuncture and Nurse-led supportive care in Neoplasms and Palliative Care, sponsored by British Columbia Cancer Agency. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-10-20.

Sponsored by British Columbia Cancer Agency · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Research question: Can acupuncture improve symptom control and quality of life (QOL) in patients with advanced incurable cancer?

The purposes of this study is to investigate the feasibility of performing a randomized trial with acupuncture in improving symptom control and quality of life (QOL) in patients with advanced incurable cancer at the BC Cancer Agency, Vancouver Island Centre in Victoria.

We will:

  • Evaluate whether subjects who are receiving palliative care for cancer related symptoms can tolerate and complete to a course of acupuncture treatments.
  • Evaluate whether it is possible to conduct a study using acupuncture on cancer patients.
Read the detailed description

Patients with advanced cancer suffer from many symptoms which dramatically reduce their Quality of Life (QOL). There have been significant improvements in the management of pain, nausea and constipation, but other common symptoms such as fatigue, anxiety, depression, and a lack of well-being are not readily addressed by conventional therapies. As cancer patients usually present with numerous symptoms, it would be important to try to address all of these globally, instead of only treating individual symptoms that respond well to conventional therapy. Attempts at controlling individual symptoms can also give rise to iatrogenic effects. One well known example is constipation occurring in patients who are on opiate analgesics. Successful treatment from the caregiver's perspective is often scored against each individual symptom that is being treated. From the patient's point of view, it is the interplay of the whole treatment package that succeeds or fails in improving his QOL

In an attempt at treating all of the patient's symptoms, research into the use of complementary and alternative medicine (CAM) has been conducted to determine the utility of these treatments in addressing the unmet needs of many patients with cancer. There is preliminary evidence that acupuncture in particular, is successful at improving many cancer and treatment associated symptoms.

Given the potential to improve symptom control and QOL, it is thought that acupuncture should be investigated to assess its effectiveness and feasibility in symptomatic patients with advanced cancer. Acupuncture should be compared against another intervention, so that the control group would also be receiving attention to their symptoms. As supportive care has been shown to be helpful in ameliorating symptoms in terminal care, acupuncture will be compared against this intervention. Sham acupuncture is not considered to be a good comparison for acupuncture as it is not well tested, and its effects are often indistinguishable from acupuncture. Recently however, some studies have reported the use of novel techniques that prevent acupuncture-naïve patients from distinguishing between acupuncture treatment and placebo. These techniques have yet to be independently validated.

Objectives: 1. To determine feasibility of recruiting patients and running a randomized study that involves acupuncture at the BCCA-VIC. 2. To gather enough data to support a grant application to fund a larger study to look at the effectiveness of acupuncture as adjunctive treatment for the management of symptoms associated with palliative cancer care.

02

Conditions studied

  • Neoplasms
  • Palliative Care

Keywords

  • Palliative Care
  • Acupuncture
  • Symptom Management
  • Quality of Life
03

In context

Lead sponsor

British Columbia Cancer Agency is the lead sponsor of 149 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients receiving palliative therapy for incurable cancer
  • anticipated survival of at least 3 months
  • able to complete ESAS sheet unaided
  • ESAS of 5 or more in at least one of the following symptoms; fatigue, depression, anxiety and lack of wellbeing

Exclusion criteria

Exclusion Criteria:

  • refuse to receive weekly acupuncture for 4 weeks
  • refuse to receive nursing support for 4 weeks
  • known to have impaired clotting of blood
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Nurse-led supportive care

    Visit with a Palliative Care nurse once weekly for 4 weeks

    Behavioral: Nurse-led supportive care

  • Experimental
    Acupuncture

    Patients received acupuncture once a week for 4 weeks.

    Procedure: Acupuncture

Interventions

  • ProcedureAcupuncture

    Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.

  • BehavioralNurse-led supportive care

    20-30 minutes of supportive attention from an experienced palliative nurse.

06

What researchers measure

Primary outcomes

  1. The change in Edmonton Symptom Assessment Score (ESAS) after intervention (ESAS at baseline - ESAS at first follow up) will be analysed for each of the 4 symptoms (fatigue, anxiety, depression, a lack of well-being) under investigation. Results will be

Secondary outcomes

  1. Determine the % of patients suitable, and the % of patients who consent to be recruited.

  2. Determine the % of patients who complete all 4 intervention sessions.

  3. Determine the duration of change in ESAS after intervention (ESAS at second and third follow-up - ESAS at first follow up).

07

Study locations

1 site
  • BC Cancer Agency - Vancouver Island Centre
    Victoria, British Columbia V8R 6V5, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 20, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00302185
Lead sponsor
British Columbia Cancer Agency
First posted
Mar 14, 2006
Start date
Jun 2007
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Oct 20, 2010

Study contacts

Jan T Lim, MD
principal investigator · BC Cancer Agency and University of British Columbia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion